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Abstract
Background: The correlation between ALK gene copy number gain (ALK-CNG) and prognosis in the context of
advanced non-small-cell lung cancer (NSCLC) remains a controversial issue. This study aimed to evaluate the
association among ALK-CNG according to Fluorescent In Situ Hybridization (FISH), clinical characteristics and
survival in resectable and advanced NSCLC.
Methods: Clinical and pathological data of patients with resectable and advanced NSCLC were retrospectively
collected. Tumor tissues were analyzed for ALK-CNG by FISH, and patients were divided in 3 groups/patterns
on the basis of ALK signals: disomic [Pattern A], 3–7 signals [Pattern B], >7 signals [Pattern C]. The association
between clinical and pathological features and ALK-CNG patterns was evaluated. Disease/progression-free and
overall survival (DFS/PFS and OS) were estimated using the Kaplan-Meyer method.
Results: A number of 128 (76.6 %) out of the 167 eligible patients were evaluable for ALK-CNG, displaying
pattern A, B and C in 71 (42.5 %), 42 (25.1 %) and 15 (9 %) patients, respectively. Gains in ALK-CNG appear to
be more frequent in smokers/former smokers than in non-smokers (74.2 % versus 20.4 %, respectively, p = 0.03). Pattern
A and C seem more frequently associated with higher T-stage (T3-4), while pattern B appears more represented
in lower T-stage (T 1-2) (p = 0.06). No significant differences in survival rate were observed among the above groups.
Conclusions: A high ALK-CNG pattern might be associated with smoking status and theoretically it might mirror
genomic instability. The implications for prognosis should be prospectively investigated and validated in larger
patients’ series.
Trial registration: We confirm that all the study was performed in accordance with relevant guidelines and
regulations and that all the protocol (part of a larger project MFAG 2013 N.14282) was approved by the local
Ethics Committee of the Azienda Ospedaliera Universitaria Integrata of Verona on November 11st, 2014.
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Background
Nowadays, non-small-cell lung cancer (NSCLC) might
be considered as a universe of different diseases. Particu-
larly in the context of adenocarcinoma, reliable evidence
is available suggesting that cancer development and pro-
gression might be led by the addiction from aberrant
pathways triggered by genetic abnormalities acting as
oncogenic drivers (such as the activating mutation of
EGFR or the translocation of ALK). In this setting, the
inhibition of these drivers with selective agents has radi-
cally changed the natural history of the disease [1–7].
Unfortunately, only a limited subpopulation of lung
cancer patients might benefit from this personalized
treatment. Hence, the importance of identifying and
validating new molecular alterations with prognostic and
predictive significance in order to extend the proportion
of lung cancer patients who might benefit from targeted
drugs.
ALK is a versatile oncogene whose role has been recog-
nized in a large variety of tumors through different activa-
tion mechanisms, mainly the chromosomal rearrangement
with different fusion partners (as the microtubule associ-
ated protein EML4 in NSCLC or the nucleophosmin
NPM1 in anaplastic large cell lymphoma). In NSCLC, the
successful history of ALK inhibitors started with crizotinib
and is still ongoing [8]. Crizotinib is an orally available
tyrosine kinase inhibitor (TKI) originally designed to tar-
get the mesenchymal to epithelial transition process, but
it also potently inhibits ALK and ROS1 phosphorylation
and signaling [9]. Based on encouraging preclinical data,
impressive preliminary results were published from an
expansion cohort of a phase I trial [10] and from the
PROFILE 1005 phase II trial [11]. In the second-line
trial PROFILE 1007, 347 patients with ALK-rearranged
NSCLC pretreated with a platinum doublet received
either crizotinib or second-line chemotherapy with
docetaxel or pemetrexed. Patients benefited from crizo-
tinib in both terms of overall response rate (ORR)
(65 % versus 20 %; p < 0.001) and median progression-free
survival (PFS) (7.7 versus 3.0 months; HR 0.49; p < 0.001)
[6]. Moreover, in the first-line phase III trial PROFILE
1014, 343 treatment-naive patients with ALK-rearranged
NSCLC were randomized to receive either crizotinib
or standard platinum-based plus pemetrexed first-line
chemotherapy. Also in this setting, crizotinib met not
only the primary end point, achieving a significantly
longer median PFS (10.9 versus 7.0 months; HR 0.45;
p < 0.001), but also a significantly higher ORR (74 %
versus 45 %; p < 0.001). The more frequent adverse
events associated with the administration of crizotinib
were vision disorders, diarrhea, edema, increased ami-
notransferase levels and neutropenia [7]. The main
limitations of the crizotinib efficacy are represented by
its low brain penetrance and its inactivity against
secondary mutations of the ALK gene. Therefore, clinical
trials evaluating next generation ALK inhibitors are cur-
rently ongoing. Promising response rates and PFS have
been reported particularly in crizotinib-refractory ALK-
rearranged NSCLC patients treated with ceritinib [12–14],
alectinib [15, 16], brigatinib [17] and lorlatinib [18]. Re-
cently, the pre-planned interim analysis of the J-ALEX
trial, demonstrated the superiority of alectinib to crizo-
tinib in untreated ALK-rearranged NSCLC patients
(median PFS not reached versus 10.2 months; HR 0.34;
p < 0.0001) [19].
Another ALK aberration, the gene copy number gain
(CNG), has been identified in several tumor types and
significantly correlated with poor prognosis and/or ad-
vanced disease status.
In this regard, ALK-CNG has been reported in the
10 % of renal cell carcinoma patients and the presence
of more than 5 copies of the ALK gene was significantly
associated with high tumor size, nuclear grade and
worse 10-years survival rate [20]. In colorectal cancer
patients, ALK-CNG was found in the 3.4 % of non-
molecularly selected patients and in the 37 % of RAS-
BRAF-PI3KCA wild-type patients [21, 22]. In both
studies, the ALK gene copy number increase was
significantly associated with poor prognosis. Moreover,
in triple wild-type patients, the response rate to cetuxi-
mab or panitumumab was significantly higher in the
subgroup of disomic ALK (70 %) as compared with
ALK-CNG subgroup (32 %), with similar results in term
of PFS and overall survival (OS), raising the hypothesis
of a possible role of ALK-CNG in resistance to anti-
EGFR therapy [21, 22]. ALK-CNG was further identi-
fied in the 13 % of patients affected by hepatocellular
carcinoma, negative for serum hepatitis B virus DNA, with
a significant correlation among ALK-CNG (≥4 copies
versus < 4 copies), 3-year PFS rate (27 % versus 42 %) and
3-year OS rate (18 % versus 47 %) [23]. In rhabdomyosar-
coma (RMS), ALK-CNG was detected in the 88 % of
alveolar RMS and in the 52 % of embryonal RMS (ERMS).
In ERMS, specific ALK gain in the primary tumor corre-
lated with metastatic disease and poor 5-year disease-
specific OS (62 versus 82 %) [24]. Moreover, ALK-CNG
was retrospectively detected in the 47.2 % of patients with
inflammatory breast cancer and significantly correlated
with worse overall survival (24.9 versus 38.1 months) and
recurrence free survival (RFS) after curative mastectomy
(12.7 versus 43.3 months) compared to ALK-CNG nega-
tive patients [25]. Finally, an aberrant activation of ALK,
both by activating mutation and amplification, might
drive the tumorigenesis of neuroblastoma (NBL) [26].
In a retrospective analysis of pediatric patients with
NBL, ALK amplification due to polyploidy (ALK/CEP2
ratio > 4) represented a negative prognostic factor for
OS [27].
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Regarding lung cancer, the presence and potential
prognostic role of the different ALK gene aberrations
(translocation and gene copy number gains) have been
widely investigated with debatable results (as more ex-
tensively revised in the discussion paragraph). Our study,
retrospectively conducted in a large series of NSCLC
patients, aimed to investigate the potential correlation
between ALK-CNG and clinical features, exploring in
particular the prognostic implications of this genetic
abnormality in resected and advanced NSCLC patients.
Methods
Patients and samples
All the reported data of this study were obtained from
the Lung Verona Database (Verona, Italy). Clinical
(gender, familiarity, comorbidity, performance status,
smoking history, treatment) and pathological (TNM,
disease stage, grading) information has been collected.
All the cases were classified according to WHO criteria
[28]. Appropriate samples, containing at least 90 %
neoplastic cells, have been selected for the interphase
cytogenetic and molecular studies.
Interphase fluorescence in situ hybridization (FISH)
analysis
ALK gene status assessment by break-apart probe
Interphase cytogenetic analysis was performed by FISH
using 5 μm sections from formalin-fixed and paraffin-
embedded tissues and a commercially available break-
apart ALK kit (Abbott-Vysis) that uses two DNA probes
on the ALK gene, one at the 3’ and one at the 5’ regions.
The slides were examined using an Olympus BX61
(Germany) with appropriate filters for SpectrumOrange,
SpectrumGreen and the UV filter for the DAPI nuclear
counterstain. The signals were recorded with a CCD
camera (CytoVysion, Olympus) and digitalized by Fluo/
D-SIGHT (Menarini/Visia Imaging). A total of 150 neo-
plastic nuclei were assessed in at least three different
areas for surgical specimens. In bioptic samples all neo-
plastic nuclei (on average 60 nuclei) were evaluated.
Nuclei harboring split-signals were scored as positive for
ALK rearrangement using the approved cut-off (15 %).
Gene copy number was initially scored per each case.
Control probes using centromeric alpha-satellite specific for
chromosome 2, 3 and 17 (CEP2, CEP3 and CEP17) probes
Centromeric alpha-satellite specific for chromosome 2, 3
and 17 (CEP2, CEP3 and CEP17) were used as control
probes (Vysis-Abbott, Olympus, Rome, Italy). Control
probes polysomy was detected by performing FISH assay
on adjacent serial tissue sections. Briefly, each probe was
diluted 1:10 in tDenHyb2 buffer (Insitus, Albuquerque,
NM). Ten microliters of diluted probe were applied to
each slide and cover slips were placed over the slides.
Denaturation was achieved by incubating the slides at
80 °C for 10 min in a humidified box; then hybridization
was done at 37 °C for 16 h. The cover slips were then re-
moved and the slides were immersed at room temperature
in 0.5 x SSC (Superconducting Super Collider) for 2 min
and in 2 x SSC for 2 min. The slides were air dried and
counterstained with 10 μl DAPI/Antifade (DAPI in
Fluorguard, 0.5 μg/ml, Insitus, Albuquerque, NM).
Fluorescent in situ signals were evaluated on carcino-
matous and normal pulmonary adjacent parenchyma. A
total of 150 neoplastic nuclei were assessed in at least
three different areas for surgical specimens while 60
neoplastic nuclei were evaluated in bioptic samples.
ALK interpretation
Mean copy number for the ALK locus (LSI) and the
centromeric (CEPs) probes CEP2, CEP3 and CEP17 were
primarily evaluated. A mean copy number of centro-
meric probes were secondly detected to assess ploidy.
Ratio between mean copy number of ALK gene and
mean copy number of control centromeric probes CEP2,
CEP3 and CEP17 was finally scored. Amplification of
the ALK locus gene was interpreted when the ratio
(LSI/CEPs) was ≥ 2. When increasing gene copy num-
ber resulted < 2 after corrections by control probes
(LSI/CEPs) the case was interpreted as having gains of
chromosome due to polyploidy. Cases were digitalized
by using the scan D-Sight/Fluo instrument (VisiaImaging,
Florence, Italy).
Statistical analysis
According to what stated by the Cytogenetics Laboratory
of Verona’s University about the frequency distribution
of ALK expression as a cytogenetic profile [29], patients
were divided in three groups on the base of gene copy
number (Pattern A: CNG = 2 [disomic]; Pattern B: CNG
3-7; Pattern C: CNG >7). The Fisher’s Exact Test (with a
significance α error of 0.5) was applied to evaluate the
correlation of ALK-CNG subgroups with the clinico-
pathologic variables in the overall population and the
treatment outcome in metastatic patients. In order to
correct possible biases due to the disease stage frequen-
cies, patients were divided in resected (those who under-
went surgery for an operable disease) and metastatic
patients (metastatic from the diagnosis). The prognostic
analysis has been performed separately for these two
groups. The hazard ratio (HR) and the 95 % confidence
intervals (95 % CI) were estimated for each variable
using the Cox univariate model. The OS (2-year survival
rate) was calculated using the Kaplan Meyer’s method to
identify a possible correlation between clinical outcome
and expression of ALK. We estimated the disease free
survival (DFS) for resected patients and the PFS for pa-
tients who underwent systemic treatment for metastatic
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disease. Finally, Kaplan Meyer curves were compared
through Long Rank test and all the analyses were con-
ducted using SPSS 18.0 software.
Results
Patients’ characteristics
A consecutive series of 205 NSCLC (112 biopsies, 93
surgical specimens) were collected from the Lung Verona
Database. Thirty-eight patients with locally advanced or
metastatic NSCLC harboring EGFR activating mutations
and ALK rearranged tumors were excluded from the ana-
lysis. We analyzed a total of 167 patients and their clinico-
pathological characteristics are summarized in Table 1.
One hundred and six men (63.5 %) and 61 women
(36.5 %) with a median age of 66 years (ranging from 29
to 85) were included. Among them, 56 patients (33.5 %)
were smokers, 68 former smokers (40.7 %), 34 never
smokers (20.4 %), while 9 patients (5.4 %) were not eva-
luable for smoking status; the 60.5 % of patients had fa-
miliarity for cancer; 25.7 % had cardiac and respiratory
comorbidities. One hundred and one patients (60.4 %)
were metastatic at the diagnosis; 26 patients (15.5 %)
were stage I, 10 (6.1 %) stage II and 30 (18.0 %) stage
III. The predominant histological subtype was adeno-
carcinoma with 147 cases (88 %), followed by squamous
cell carcinoma with 7 cases (4.2 %) and mixed or other
histotype were 11 cases (6.6 %). Among those patients
evaluable for histologic tumor grade (69/167), 25.1 %
were poor differentiated (G3). The majority of patients
Table 1 Patients’ characteristics (167 evaluable patients for the
clinical analysis)
Patients number (%)
Gender
Male 106 (63.5)
Female 61 (36.5)
Cancer familiarity
Yes 101 (60.5)
No 43 (25.7)
Unknown 23 (13.8)
Comorbidity
Yes 52 (31.1)
No 115 (68.9)
Performance Status sec. ECOG
0 99 (59.3)
1 36 (21.6)
2–3 12 (7.1)
Unknown 20 (12.0)
Histology
Adenocarcinoma 147 (88.0)
Squamous 7 (4.2)
Other/Mixed 13 (7.8)
T descriptor according to TNM
1–2 102 (61.1)
3–4 65 (39.9)
N descriptor according to TNM
0 36 (21.6)
1 19 (11.4)
2 66 (39.5)
3 46 (27.5)
M descriptor according to TNM
0 66 (39.5)
1 101 (60.5)
Disease stage
I-II 36 (21.6)
III-IV 131 (78.4)
Grading
1 12 (7.2)
2 15 (9.0)
3 42 (25.1)
Unknown 98 (58.7)
Smoking status
Current 56 (33.5)
Former 68 (40.7)
Never 34 (20.4)
Unknown 9 (5.4)
Table 1 Patients’ characteristics (167 evaluable patients for the
clinical analysis) (Continued)
Starting treatment
Surgery 47 (28.1)
Neoadjuvant 3 (1.8)
Chemo-radiotherapy 17 (10.2)
Chemotherapy 75 (44.9)
Support therapy 25 (15.0)
Response rate to 1st line therapy
CR 3 (1.8)
PR 31 (18.6)
SD 20 (12.0)
PD 35 (21.0)
NP 78 (46.6)
ALK-CNG
disomic 71 (42.5)
3–7 copies 42 (25.1)
>7 copies 15 (9.0)
NA 39 (23.4)
CR complete response, PR partial response, SD stable disease, PD progressive
disease, NP not performed, CNG copy number gain, NA not available
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were in good clinical conditions with PS 0 (59.3 %) and
1 (21.6 %), while only the 7.1 % of patients were PS 2 or
PS 3. Forty seven patients (28.1 %) affected by localized
disease underwent surgery, in some cases followed by
adjuvant chemotherapy; 3 patients were treated with
neoadjuvant chemotherapy before surgery. Locally ad-
vanced patients were treated with chemo-radiotherapy
in 17 cases (10.2 %). Seventy-five patients (44.9 %) with
advanced disease were treated with chemotherapy tailored
on the basis of histologic type, age, comorbidities and
performance status. Overall, 89 patients with advanced
disease were treated with I line chemotherapy, among
them 3 patients (1.8 %) had complete response (CR), 31
(18.6 %) had partial response (PR), 20 (12 %) had stable
disease (SD) and 35 patients (21 %) progressive disease
(PD) (Table 1).
Analysis of ALK gene copy number status
In the overall cohort of patients, 128 were available for
ALK-CNG analysis. Fifty-seven cases (34.1 %; 95 % CI
34.2-47.7) showed ALK-CNG. We observed three clus-
tered patterns of fluorescent signals (Fig. 1), applying the
technique employed by our group for the study of the
3q chromosomal amplification in squamous cell lung
carcinoma [29]. Fifteen patients (9.0 %) showed pattern
C (>7 ALK fluorescent signals, ranging from 7 to 12)
(Fig. 1-a); 42 patients (25.1 %) showed pattern B (from 3
to 7 ALK-CNG signals) (Fig. 1-b) and, as expected, the
largest part of the samples (71 patients, 42.5 %) had
pattern A (disomic) (Fig. 1-c) (Table 1). The three ALK
patterns were interpreted using the control CEP2, CEP3
and CEP17 probes. Among pattern C, the 13 % (2 cases)
showed a ratio ≥ 2 when corrected by CEP3 and CEP17.
In the remaining 13 out of 15 cases with pattern C and
in all the cases with pattern B the FISH results mirrored
the mean number of centromeric signals with a final ra-
tio < 2, classifiable as polyploidy. The only 2 cases showing
ALK gene amplification were visible at fluorescent micro-
scope as double minutes rather than homogeneously
staining regions pattern.
Association analysis between clinico-pathological
characteristics of patients and ALK-CNG
No statistically significant correlations were observed
between the three ALK-CNG patterns and the majority
of the clinico-pathological characteristics (such as gender,
histology, grading, comorbidity, cancer familiarity, per-
formance status sec. ECOG) (Table 2). Nevertheless, the
association analysis demonstrated that ALK-CNG, pattern
B in particular, is more frequently detected in smokers
and former smokers compared to never smoker patients
(p = 0.03). Similarly, ALK-CNG seems to correlate with
the primary tumor extension (T descriptor). Small tumors
(T1 and T2) were more frequently detected in association
with ALK-CNG pattern B compared to T3 and T4 tumors
(43.1 % versus 22.8 %). No significant association has been
observed between ALK-CNG and node (N descriptor) or
metastatic (M descriptor) status. Although no statistically
significant association has been reported between ALK-
CNG and disease stage, early stages (I and II) are more
represented in ALK pattern B, whereas in pattern C
advanced diseases are more frequently detected (1 case
stage I versus 14 cases stage III-IV). No well differentiated
diseases (G1) have been observed in ALK pattern C
subgroup (versus 8 cases G2-3). No difference in term of
response to first line chemotherapy has been observed
according to the different ALK-CNG patterns.
Prognostic analysis
When all the 128 patients evaluable for the ALK analysis
were stratified according to ALK-CNG pattern, no sig-
nificant difference was observed in terms of survival rate
at 2 years (Fig. 2). Among resected patients, although no
statistically significant difference was observed, a survival
advantage for those patients with ALK-CNG pattern B
has been reported (2-year OS 69.5 % versus ≤50 % for
pattern A and C) (Fig. 3a). Among metastatic patients,
the worst survival was observed for the subgroup of
patients with ALK-CNG pattern C (2-year OS 0 % versus
27.0 % and 39.1 % for pattern B and A, respectively)
(Fig. 3b). The 1-year DFS among resected patients was
Fig. 1 FISH findings in cell neoplastic nuclei. a Nucleus with >7 ALK fluorescent signals; b Nuclei with polysomy of ALK (from 3 to 7 ALK-CNG signals);
c Nuclei with a disomic pattern of ALK
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Table 2 Association analysis between clinico-pathological characteristics and ALK-CNG
Clinico-pathological parameters ALK-CNG - patients number (%) p-value
Disomic 3–7 >7 Total
Gender 128 0.59
Male 41 (51.9) 28 (35.4) 10 (12.7) 79 (100.0)
Female 30 (61.2) 14 (28.6) 5 (10.2) 49 (100.0)
Cancer familiarity 110 0.44
No 18 (54.5) 13 (39.4) 2 (6.1) 33 (100.0)
Yes 41 (53.2) 25 (32.5) 11 (14.3) 77 (100.0)
Smoking status 120 0.03
Never 20 (80.0) 4 (16.0) 1 (4.0) 25 (100.0)
Current 24 (54.5) 13 (29.5) 7 (15.9) 44 (100.0)
Former 22 (43.1) 23 (45.1) 6 (11.8) 51 (100.0)
Comorbidity 121 0.19
No 23 (67.6) 8 (23.5) 3 (8.8) 34 (100.0)
Yes 43 (49.4) 33 (37.9) 11 (12.6) 87 (100.0)
Performance Status sec. ECOG 112 0.63
0 43 (57.3) 24 (32) 8 (10.7) 75 (100.0)
1 12 (42.9) 11 (39.3) 5 (17.9) 28 (100.0)
2–3 6 (66.7) 2 (22.2) 1 (11.1) 9 (100.0)
Histology 128 0.83
Adenocarcinoma 63 (55.8) 38 (33.6) 12 (10.6) 113 (100.0)
Squamous 3 (50.0) 2 (33.3) 1 (16.7) 6 (100.0)
Other 5 (55.6) 2 (22.2) 2 (22.2) 9 (100.0)
T descriptor 115 0.06
1–2 28 (48.3) 25 (43.1) 5 (8.6) 58 (100.0)
3–4 36 (63.2) 13 (22.8) 8 (14.0) 57 (100.0)
N descriptor 108 0.52
0 10 (45.5) 10 (45.5) 2 (9.1) 22 (100.0)
1–2–3 47 (54.7) 28 (32.6) 11 (12.8) 86 (100.0)
M descriptor 128 0.85
0 29 (58.0) 16 (32.0) 5 (10.0) 50 (100.0)
1 42 (53.8) 26 (33.3) 10 (12.8) 78 (100.0)
Disease stage 126 0.14
I–II 12 (48.0) 12 (48.0) 1 (4.0) 25 (100.0)
III–IV 57 (56.4) 30 (29.7) 14 (13.9) 101 (100.0)
Grading 54 0.62
1 5 (55.6) 4 (44.4) 0 (0) 9 (100.0)
2 4 (33.3) 6 (50.0) 2 (16.7) 12 (100.0)
3 15 (45.3) 12 (36.4) 6 (18.2) 33 (100.0)
Response rate to 1st line therapy 73 0.92
No 28 (62.2) 12 (26.7) 5 (11.1) 45 (100.0)
Yes 17 (60.7) 7 (25.0) 4 (14.3) 28 (100.0)
CNG copy number gain
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increased for those patients with ALK-CNG pattern B
(80.0 %) compared to those patients with pattern A
(39.8 %) and C (26.7 %) (Fig. 3C). The 1-year PFS among
advanced patients did not significantly differ according
to the ALK-CNG pattern (15.8 % for pattern A, 19.6 %
for pattern B and 38.9 % for pattern C) (Fig. 3D). The
univariate analysis confirmed the lack of a statistically
significant difference in term of survival according to the
ALK-CNG pattern (Table 3). At the univariate analysis,
disease stage I-II, tumor size 1-2, negative nodes and
surgery were significant predictors for longer DFS in
resected patients; whereas performance status 0-1 pre-
dicts longer PFS and, together with response to first line
chemotherapy and lack of synchronous metastases, longer
OS in advanced patients (Table 3).
Discussion
Our analysis aimed to investigate the potential correl-
ation between ALK-CNG and clinical features, exploring
the prognostic implications of ALK-CNG in a retro-
spective cohort of 167 NSCLC patients. We decided to
exclude from the analysis patients harboring EGFR
mutant and ALK rearranged NSCLC in order to avoid
additional confounding factors reducing the reliability of
the prognostic analysis. In fact, to evaluate the prognos-
tic effect of ALK and EGFR alterations, patients should
not be treated with the selective inhibitors commonly
used in clinical practice, because the benefit deriving
from these agents might mask the prognostic value of
the biomarker in-study. Overall, ALK-CNG was ob-
served in the 34.1 % of cases. The 25.1 % of the samples
showed ALK fluorescent signal ranging from 3 to 7 and,
for all of them, the ALK-CNG was due to polyploidy
(ALK/CEPs ratio < 2), whereas only 9 % of tumors showed
ALK fluorescent signal > 7. Therefore, similarly to what
demonstrated by our group in the study of the 3q
chromosomal amplification in squamous cell lung car-
cinoma [29], ALK-CNG seems mostly related to poly-
ploidy (whole DNA reduplication) rather than locus
specific gene amplification.
As reported in other retrospective studies [24], our
results suggest a correlation between ALK-CNG and
early stage disease (the majority of T1 tumors clusterize
in pattern B, none in pattern C). Moreover, smokers and
former smokers showed an increased probability to
harbor an ALK-CNG compared to never smokers, which
are in the 80 % of cases identified in pattern A. These
findings support the hypothesis that ALK-CNG might
represent a marker of chromosomal instability appearing
early in NSCLC carcinogenesis and potentially triggered
by cigarette smoking.
Although no definitive conclusions can be drawn from
the results of our prognostic analysis, some interesting
hypotheses emerged regarding the intrinsic biological
features of the three ALK-CNG patterns, potentially
reflecting different levels of chromosomal instability. In
fact, while for ALK-CNG pattern B a greater 1-year DFS
(80.0 %) and 2-year OS (69.5 %) clearly emerged in
resected tumors, conversely, for pattern C, the DFS rate
was very low (26.7 %) and in the metastatic setting none
of these patients survives at 2 year time-point. Regarding
the PFS, the greater 1-year PFS observed in patients with
ALK-CNG pattern C (38.9 % versus 19.6 % for pattern A
and 15.8 % for pattern B) might reflect the higher
chemo-sensitivity of these tumors featured by a strong
chromosomal instability. Although in our work we
calculate a 2-year survival rate, future studies should be
performed with long-term survival outcomes in order to
reliably evaluate the prognostic role of a biomarker for
clinical setting.
Similarly to our analysis, some other studies evaluating
the incidence and potential prognostic implications of
ALK gene aberrations have been performed in lung
cancer with debatable results. In the context of a retros-
pective analysis of 107 NSCLC cases, ALK amplification
(>5 copies of ALK per cell in 10 % of analyzed cells) and
ALK-CNG (mean copy number of 3–5 in 10 % of cells)
were identified in the 10 % and 63 % of NSCLC patients,
respectively. Although no significant correlation between
ALK and clinico-pathological features or prognosis
emerged, a significant association between ALK amplifi-
cation and early stage has been reported, supporting the
hypothesis that ALK amplification might represent an
early genetic event in NSCLC and potential marker of
genomic instability [30]. In a retrospective analysis of 20
pulmonary sarcomatoid carcinomas (PSC), the frequency
Fig. 2 Kaplan Meyer curves for OS in the overall population stratified
according to ALK pattern A, B and C
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of ALK-CNG was significantly higher compared to
NSCLC with adenocarcinoma histology (22 % versus
0.02 %) with a mean copy number gain of 7 and a sig-
nificant association with chromosome 7 (EGFR) and 17
(HER2) polysomy. This finding suggests the implication
of ALK-CNG as an oncogenic event in PSC, potentially
correlated with epithelial-mesenchymal transition and
sarcomatoid differentiation [31]. Future confirmation of
the oncogenic role of ALK-CNG could support the de-
sign of selective studies exploring the potential activity
of the ALK inhibition in PSC. Another study conducted
in patients with NSCLC and brain metastases reported
ALK-CNG in the 11 % of cases with an interesting
increased ALK-CNG in brain metastases compared to
primary tumors, supporting the rationale of ALK-CNG
as a genetic aberration connected to aggressiveness and
metastatic behavior [32]. Moreover, in a large retros-
pective analysis of 1500 NSCLC patients, ALK-CNG
(mean native copy number ranged from 2 to 7) was re-
ported in the 80 % of cases and was significantly more
common in ALK non-rearranged tumors compared to
the translocated ones (62 % versus 19 %). Furthermore,
as observed in our analysis, ALK-CNG was mostly related
to polysomy, whereas focal amplification was a rare event
(<2 % in ALK non-rearranged tumors) [33]. Regarding
ALK inhibitors, ALK-CNG, besides representing a marker
of insensitivity to crizotinib, was reported to be a mechan-
ism of resistance to crizotinib in ALK-translocated
NSCLC both in vitro [34] and in patients progressing dur-
ing crizotinib treatment [35]. To summarize, our analysis
supports the fact that, although ALK pattern B seems to
appear early in the tumorigenesis of NSCLC and might
Fig. 3 Kaplan Meyer curves stratified according to ALK pattern A, B and C for OS and DFS in resected patients (a-c) and for OS and PFS in
metastatic patients (b-d)
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mirror an early genomic instability, an high ALK gene
copy number (>7, pattern C) related to polyploidy, could
be considered as a cut off to discriminate genomically
unstable and smoking-related NSCLC featured by an
aggressive biological behavior, frequently in advanced
stage and with a poor awaited prognostic outcome.
Conclusion
Although limited by the retrospective nature, the results
of our analysis are able to generate interesting hypotheses
regarding the biological behavior and the potential thera-
peutic implication of ALK genetic aberrations, ALK-CNG
in particular. As observed in other studies, our analysis
confirms that a high ALK gene copy number gain is not a
driver genetic event in lung cancer tumorigenesis but it
might represent a marker of chromosome instability, cor-
related with an aggressive metastatic behavior. In this
regard, early pathogenic events probably induce different
ALK aberrant NSCLC. The ALK non-translocated tumors
are frequently associated with chromosomal instability
and ALK-CNG, whereas the ALK-translocated NSCLC
presents a low native ALK copy number and the increase
in ALK-CNG emerges as a mechanism of resistance to
crizotinib treatment. Unfortunately, conversely to ALK
and ROS1 translocations that are widely recognized
oncogenic drivers in a small subset of NSCLC able to
predict sensitivity to specific inhibitors, ALK-CNG rep-
resents a candidate mechanism of resistance to this tar-
get therapy. Therefore, it is mandatory to clarify the
role and mechanism of this genetic aberration in order
to identify and validate effective therapeutic approaches
in this subpopulation of lung cancer patients harboring
ALK-CNG. In this context, our analysis is conceived
and designed as a further step towards a more biologic-
ally rationale approach to treat NSCLC patients. The
implications for prognosis should be prospectively in-
vestigated and validated in larger patients’ series.
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Table 3 Univariate analysis
Variables Disease free survival Cancer specific survival Overall survival
HR 95 % CI P HR 95 % CI P HR 95 % CI P
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1.478 0.60–1.47 0.395 1.782 0.85 - 3.69 0.121 1.332 0.79–2.23 0.278
Comorbidity
[no versus yes]
1.395 0.65–2.96 0.388 - - - - - -
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[Disomic/3-7 versus > 7]
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Disease stage
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Response rate to 1st line
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- - - - - - 2.356 1.31–4.23 0.004
HR hazard ratios, CI confidence intervals, CNG copy number gain
aThe results of the univariate analysis are not significant even categorizing individually the variables [disomic versus 3–7 versus > 7]
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